IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Observe the safety/tolerability and effectiveness in terms of response rate and duration of
response of the combination pasireotide + everolimus in the treatment of patients with
relapsed/refractory multiple melanoma.